Cullinan Therapeutics, Inc. 2025 10-K: Key Highlights for Investors
Cullinan Therapeutics, Inc. 2025 Annual Report (10-K): Detailed Highlights and Shareholder Insights
Key Points from the 2025 10-K Filing
-
Annual Report Filing: Cullinan Therapeutics, Inc. filed its 10-K for the fiscal year ended December 31, 2025. The report was prepared in accordance with the requirements of the Securities Exchange Act of 1934.
-
Public Float and Share Count: As of June 30, 2025, the aggregate market value of voting and non-voting common stock held by non-affiliates was \$442.2 million, based on the Nasdaq Global Select Market closing price. As of February 23, 2026, there were 60,526,128 shares of common stock outstanding.
-
Company Status: Cullinan is classified as an Accelerated Filer and a Smaller Reporting Company. It is not a well-known seasoned issuer or an emerging growth company.
-
SEC Compliance: The company has filed all required reports in the past 12 months and is in compliance with Interactive Data File requirements.
-
No Error Restatements: The 10-K does not contain corrections or restatements relating to previously issued financial statements.
-
Documents Incorporated by Reference: Portions of the upcoming 2026 proxy statement will be incorporated into this 10-K.
Potentially Price-Sensitive and Shareholder-Relevant Information
-
Forward-Looking Statements: The report contains numerous forward-looking statements regarding strategy, future operations, financial condition, market growth, and product development. These are subject to risks and uncertainties, and actual results may differ materially from projections.
-
Risks Highlighted:
- Commercial success, cost, and timing of approval for clinical-stage product candidates.
- Uncertainties in global economic conditions, especially related to international trade and supply chain issues, could affect expenses, manufacturing, and trials.
- Ability to commercialize current and future product candidates, including building a specialty sales force.
- Dependence on key personnel and ability to retain/recruit talent.
- Requirement for substantial additional funding to continue R&D and commercialization. Failure to raise capital could delay or halt operations.
- Dependence on successful strategic collaborations and milestone payments, notably from Taiho Pharmaceutical Co., Ltd.
- Licensing and collaboration agreements may limit the company’s ability to sell subsidiaries or assets or enter new alliances.
- Ongoing losses since inception, and expectation of continued losses for several years.
-
Not a Shell Company: Cullinan has confirmed it is not a shell company under SEC rules.
Summary of Material and Other Risks
- Limited Operating History: Investors may find it challenging to assess the company’s future viability based on limited historical performance.
- Significant and Ongoing Losses: The company has not achieved profitability and expects to continue incurring losses for the foreseeable future.
- Funding Needs: Substantial additional capital will be required for product development and commercialization. Inability to secure funding could result in delayed programs or reduced operations.
- Pipeline Risks: Success in building a commercially viable pipeline is not guaranteed.
- Contractual Constraints: Certain agreements could delay or limit strategic actions, including asset sales or new collaborations.
- Talent Dependence: The company’s future is highly dependent on retaining key personnel.
Additional Details for Investors
-
Nasdaq Listing: Cullinan’s common stock (par value \$0.0001 per share) is listed on the Nasdaq Global Select Market.
-
Proxy Statement: A definitive proxy statement for the 2026 Annual Meeting will be filed within 120 days of the fiscal year end, with certain sections incorporated into this 10-K.
-
Corporate Structure: References to “Cullinan,” “Cullinan Therapeutics,” “we,” “us,” and “our” denote Cullinan Therapeutics, Inc. and its consolidated subsidiaries.
Investor Takeaways
-
Funding and Profitability: The company’s future operations are heavily dependent on securing additional funding and achieving commercial success with its pipeline. Any developments in funding, collaborations, or clinical trial outcomes could significantly move the share price.
-
Strategic Partnerships: Milestone payments, especially from Taiho Pharmaceutical, and new collaborations or licensing deals are critical to the company’s financial health and growth prospects.
-
Risks: Ongoing operational losses, the need for capital, and exposure to global economic conditions remain key risk factors for shareholders.
Disclaimer: This summary is provided for informational purposes only and does not constitute investment advice. Investors should review the full 10-K filing and consult with financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.
View Cullinan Therapeutics, Inc. Historical chart here
